Login to Your Account



Inotek looks past IOP after fixed-dose combo fails to impress in glaucoma

By Marie Powers
News Editor

Monday, July 10, 2017

The next chapter in the tale of Inotek Pharmaceuticals Corp. is all about “something strategic,” David Southwell, president and CEO, said after the phase II FDC trial of lead candidate trabodenoson and standard-of-care therapy latanoprost failed to move the needle in treating glaucoma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription